Dr. Dean J. Kereiakes looks at the evolution of PCI and advancements like the DynamX Bioadaptor in Cardiovascular Revascularization Medicine.
TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir shares 8 Presentations highlighting company's transformational technology innovations at TCT 2023.
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
The DESyne BDS Plus RCT includes 202 patients across 14 sites in Europe, New Zealand and Brazil.
Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
“Our submission for approval in Japan is an exciting milestone for the company and industry,” said Motasim Sirhan, CEO of Elixir Medical.
The trial, which includes 2,400 patients from 20 sites across Sweden, compares DynamX Bioadaptor to Resolute Onyx.
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s Dynamx Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
Clinical data demonstrates Dynamx Bioadaptor restores vessel motion and function with better effectiveness than competitors.
Elixir Medical Expands Leadership Team with Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing
Nepogodiev possesses more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascul
A study in the latest issue of Cardiovascular Revascularization Medicines hows that the DynamX™ Coronary Bioadaptor System, when uncaged, enabled rotational motion similar to nat
Elixir Medical Strengthens its Commercial Capabilities with the Addition of Ahram as Executive Vice President, International
Ahram possesses more than 25 years of leadership experience and successes in building new markets and accelerating commercialization for novel medical devices across Asia, Europe,
MILPITAS, Calif. – April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled